Design and Characterization of Fast-Dissolving Oral Film of Apixaban.

Q4 Medicine
Siva Prasad Sagili, P Phani Deepika, Eswaramma Pavuluri, N Jhancy Laxmi Bai, K Sujana Priyadarshini, Meruva Sathish Kumar, B Ramu
{"title":"Design and Characterization of Fast-Dissolving Oral Film of Apixaban.","authors":"Siva Prasad Sagili, P Phani Deepika, Eswaramma Pavuluri, N Jhancy Laxmi Bai, K Sujana Priyadarshini, Meruva Sathish Kumar, B Ramu","doi":"10.62958/j.cjap.2024.022","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Following the COVID-19 pandemic, microvascular and macrovascular thrombotic problems emerged that required anticoagulants. Apixaban (RN) is a factor Xa inhibitor that treats deep vein thrombosis and the two forms of artery diseases (coronary artery disease and peripheral artery disease).</p><p><strong>Materials and methods: </strong>The study objective was to create fast-disintegrating Apixaban Oral Thin Films (OTF) with the help of various super disintegrants to shorten disintegration time and enhance drug release in order to assist patients who have difficulty in swallowing conventional dosage forms and increase bioavailability. OTF was created using the solvent casting method. A 22 factorial design was employed in Design-Expert® software to develop an ideal formula.</p><p><strong>Results: </strong>The optimized film formula pH, drug content, disintegration time, folding endurance, and dissolution rate were estimated, and the film was subjected to a short-term stability study. The optimized formula exhibited a cumulative drug release of 93.47% in 60 sec.</p><p><strong>Conclusion: </strong>The drug's in vitro release pattern shows first-order kinetics and fickian diffusion was the mechanism of drug release. These findings supported that Apixaban OTFs offer a quick release of the medication from the administration site into the systemic circulation.</p>","PeriodicalId":23985,"journal":{"name":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62958/j.cjap.2024.022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Following the COVID-19 pandemic, microvascular and macrovascular thrombotic problems emerged that required anticoagulants. Apixaban (RN) is a factor Xa inhibitor that treats deep vein thrombosis and the two forms of artery diseases (coronary artery disease and peripheral artery disease).

Materials and methods: The study objective was to create fast-disintegrating Apixaban Oral Thin Films (OTF) with the help of various super disintegrants to shorten disintegration time and enhance drug release in order to assist patients who have difficulty in swallowing conventional dosage forms and increase bioavailability. OTF was created using the solvent casting method. A 22 factorial design was employed in Design-Expert® software to develop an ideal formula.

Results: The optimized film formula pH, drug content, disintegration time, folding endurance, and dissolution rate were estimated, and the film was subjected to a short-term stability study. The optimized formula exhibited a cumulative drug release of 93.47% in 60 sec.

Conclusion: The drug's in vitro release pattern shows first-order kinetics and fickian diffusion was the mechanism of drug release. These findings supported that Apixaban OTFs offer a quick release of the medication from the administration site into the systemic circulation.

阿哌沙班快速溶解口服膜的设计与表征
背景:COVID-19大流行后,出现了微血管和大血管血栓问题,需要抗凝药物。阿哌沙班(RN)是一种 Xa 因子抑制剂,可治疗深静脉血栓和两种动脉疾病(冠状动脉疾病和外周动脉疾病):研究目的是在各种超级崩解剂的帮助下制作快速崩解的阿哌沙班口服薄片(OTF),以缩短崩解时间并提高药物释放,从而帮助吞咽传统剂型有困难的患者并提高生物利用度。OTF 采用溶剂浇铸法制成。在 Design-Expert® 软件中采用了 22 个因子设计来开发理想配方:结果:估算了优化薄膜配方的 pH 值、药物含量、崩解时间、耐折度和溶出率,并对薄膜进行了短期稳定性研究。优化配方在 60 秒内的累积药物释放率为 93.47%:结论:阿哌沙班的体外释放模式显示出一阶动力学,费克扩散是药物释放的机制。这些研究结果表明,阿哌沙班 OTFs 可将药物从给药部位快速释放到全身循环中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
53
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信